Zusammenfassung
Der Raucheranteil in der deutschen Bevölkerung beträgt etwa 30 %. Über die Hälfe der
regelmäßigen Zigarettenraucher sterben an den Folgen des Rauchens, und die Lebenserwartung
von Rauchern ist im Vergleich zu derjenigen von Nichtrauchern um 10 Jahre reduziert.
Tabakrauchen ist der wesentliche Risikofaktor für das Bronchialkarzinom, die chronisch
obstruktive Lungenerkrankung (COPD) und begünstigt die Entstehung einer Vielzahl weiterer
Lungenerkrankungen.
Ein Entwöhnungskonzept, das sowohl pharmakologische als auch psychosoziale Unterstützung
umfasst, hat sich für COPD-Patienten als überaus effektiv erwiesen. Die Beendigung
des Tabakrauchens birgt sowohl akute Vorteile als auch längerfristige positive Effekte
auf lungenfunktionelle Parameter, Symptomatik und auf die Sterblichkeit.
Insgesamt ist die Tabakentwöhnung eine der effektivsten medizinischen Interventionen.
Sie sollte daher prioritär gefördert werden.
Abstract
More than 30 % of the German population are regular smokers, over half of whom will
eventually die of smoking-related diseases. Life expectancy is abridged by 10 years
in smokers compared to non-smokers. Smoking tobacco is the main risk factor for lung
cancer and chronic obstructive pulmonary disease (COPD) and predisposes to a number
of other lung diseases.
A smoking cessation programme including pharmacological as well as psychosocial support
is highly effective in COPD Patients. Smoking cessation improves lung function, symptoms
and mortality.
In conclusion, smoking cessation services are among the most effective medical interventions.
Thus, a sufficient supply of smoking cessation services on a population level must
be ensured.
Literatur
- 1 Bundesamt S. Leben und Arbeiten in Deutschland - Ergebnisse des Mikrozensus 2003. Wiesbaden:
Statistisches Bundesamt 2003
- 2 The Health Consequences of Smoking .A Report of the Surgeon General. 2004, U.S.
Department of Health and Human Services, Centers for Disease Control and Prevention,
National Center for Chronic Disease Prevention and Health Promotion. Atlanta, GA:
Office on Smoking and Health
- 3
Raupach T, Schafer K, Konstantinides S. et al .
Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm.
Eur Heart J.
2006;
27
386-392
- 4 European Respiratory Society. Lifting the smokescreen. Brussels: European Respiratory
Society 2006
- 5
John U, Hanke M.
Tobacco smoking attributable mortality in Germany.
Gesundheitswesen.
2001;
63
363-369
- 6
Doll R, Peto R, Boreham J. et al .
Mortality in relation to smoking: 50 years' observations on male British doctors.
Bmj.
2004;
328
1519
- 7
Parrott S, Godfrey C, Raw M. et al .
Guidance for commissioners on the cost effectiveness of smoking cessation interventions.
Health Educational Authority.
Thorax.
1998;
53 Suppl 5 Pt 2
1-38
- 8 Behr J, Nowak D. Tobacco smoke and respiratory disease. In: European Respiratory
Monograph (7) The impact of air pollution on respiratory health. S. Holgate Editor
2002, ERS: 161-179
- 9
Xu X, Dockery D W, Ware J H. et al .
Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal
assessment.
Am Rev Respir Dis.
1992;
146
1345-1348
- 10
Ryu J H, Colby T V, Hartman T E. et al .
Smoking-related interstitial lung diseases: a concise review.
Eur Respir J.
2001;
17
122-132
- 11
Janson C, Künzli N, de Marco R. et al .
Change in active and passive smoking in the EU respiratory health survey.
Eur Respir J.
2006;
27
517-524
- 12 Partnership S F. Lifting the smokescreen - 10 reasons for a smoke free Europe. Brussels:
European Respiratory Society 2006
- 13
Vineis P, Airoldi L, Veglia P. et al .
Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive
pulmonary disease in former smokers and never smokers in the EPIC prospective study.
Bmj.
2005;
330
277
- 14
Eisner M D, Klein J, Hammond S K. et al .
Directly measured second hand smoke exposure and asthma health outcomes.
Thorax.
2005;
60
814-821
- 15
Hughes J R.
Four beliefs that may impede progress in the treatment of smoking.
Tob Control.
1999;
8
323-326
- 16
Rigotti N A.
Clinical practice. Treatment of tobacco use and dependence.
N Engl J Med.
2002;
346
506-512
- 17
West R, McNeill A, Raw M.
Smoking cessation guidelines for health professionals: an update. Health Education
Authority.
Thorax.
2000;
55
987-999
- 18
Balfour D J.
Neural mechanisms underlying nicotine dependence.
Addiction.
1994;
89
1419-1423
- 19
Stein E A, Pankiewicz J, Harsc H H. et al .
Nicotine-induced limbic cortical activation in the human brain: a functional MRI study.
Am J Psychiatry.
1998;
155
1009-1015
- 20 US Department of Health and Human Services .The health benefits of smoking cessation
(DHHS Publication No. (CDC) 90 - 8516). USA: US Department of Health and Human Services,
Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention
and Health Promotion, Office on Smoking and Health 1990
- 21
Moller A M, Villebro N, Pedersen T. et al .
Effect of preoperative smoking intervention on postoperative complications: a randomised
clinical trial.
Lancet.
2002;
359
114-117
- 22
Scanlon P D, Connett J E, Waller L A. et al .
Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary
disease. The Lung Health Study.
Am J Respir Crit Care Med.
2000;
161
381-390
- 23
Wagena E J, Meer R M van der, Ostelo R J. et al .
The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary
disease: results from a systematic review.
Respir Med.
2004;
98
805-815
- 24
Kanner R E, Anthonisen N R, Connett J E.
Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers
with mild chronic obstructive pulmonary disease: results from the lung health study.
Am J Respir Crit Care Med.
2001;
164
358-364
- 25
Anthonisen N R, Skeans M A, Wise R A. et al .
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized
clinical trial.
Ann Intern Med.
2005;
142
233-239
- 26
Simmons M S, Connett J E, Nides M A. et al .
Smoking reduction and the rate of decline in FEV(1): results from the Lung Health
Study.
Eur Respir J.
2005;
25
1011-1017
- 27 Meer R M van der, Wagena E J, Ostelo R WJG. et al .Smoking cessation for chronic
obstructive pulmonary disease (Cochrane Review) In: The Cochrane Library. Chichester,
UK: John Wiley & Sons, Ltd 2004
- 28
Fiore M C.
Treating tobacco use and dependence: an introduction to the US Public Health Service
Clinical Practice Guideline.
Respir Care.
2000;
45
1196-1199
- 29
Jorenby D E, Leischow S J, Nides M A. et al .
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking
cessation.
N Engl J Med.
1999;
340
685-691
- 30
Wagena E J, Zeegers M P, Schayck C P van. et al .
Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive
pulmonary disease.
Drug Saf.
2003;
26
381-403
- 31
Jimenez-Ruiz C A, Masa F, Miravitlles M. et al .
Smoking characteristics: differences in attitudes and dependence between healthy smokers
and smokers with COPD.
Chest.
2001;
119
1365-1370
- 32 Konietzko N, Fabel H. Weißbuch Lunge 2005. Stuttgart, New York: Georg Thieme Verlag
2005
- 33
Ruff L K, Volmer T, Nowak D.
The economic impact of smoking in Germany.
Eur Respir J.
2000;
16
385-390
- 34
Rasmussen S R, Prescott E, Sorensen T I. et al .
The total lifetime costs of smoking.
Eur J Public Health.
2004;
14
95-100
- 35
Rasmussen S R, Prescott E, Sorensen T I. et al .
The total lifetime health cost savings of smoking cessation to society.
Eur J Public Health.
2005;
15
601-606
Prof. Stefan Andreas
Lungenfachklinik Immenhausen, Kreis Kassel
Robert Koch Straße 3
34376 Immenhausen
Email: sandreas@lungenfachklinik-immenhausen.de
